Development of vaccines for Marburg hemorrhagic fever

References

• Peters CJ, Zaki SR. Overview of viral hemorrhagic fevers. In: Tropical Infectious Diseases: Principles, Pathogens, and Practice. Guerrant Rl, Walker DH, Weller PF (Eds). Churchill Livingstone, PN, USA 726–733 (2006).
   Google Scholar
• Bausch DG, Ksiazek TG. Viral hemorrhagic fevers including hantavirus pulmonary syndrome. In: The Americas. Clinics in Laboratory Medicine.22(4), 981–1020, viii (2002).
   Google Scholar
• Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat. Med.10(12 Suppl.), S110–S121 (2004).
   PubMed Web of Science ®Google Scholar
• Marty AM, Jahrling PB, Geisbert TW. Viral hemorrhagic fevers. Clin. Lab. Med.26(2), 345–386 (2006).
   PubMed Web of Science ®Google Scholar
• Alibek K, Handelman S. Biohazard: the largest covert biological weapons program. In: The World. Random House, NY, USA (1999).
   Google Scholar
• Borio L, Inglesby T, Peters CJ et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA287(18), 2391–2405 (2002).
   PubMed Web of Science ®Google Scholar
• Paragas J, Geisbert TW. Development of treatment strategies to combat Ebola and Marburg viruses. Expert Rev. Anti Infect. Ther.4(1), 67–76 (2006).
   PubMedGoogle Scholar
• Feldmann H, Jones SM, Schnittler HJ, Geisbert T. Therapy and prophylaxis of Ebola virus infections. Curr. Opin. Investig. Drugs6(8), 823–830 (2005).
   PubMedGoogle Scholar
• Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev. Vaccines2(6), 777–789 (2003).
   PubMedGoogle Scholar
• Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol.3(8), 677–685 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J. Virol.77(18), 9733–9737 (2003).
   PubMed Web of Science ®Google Scholar
• Siegert R, Shu HL, Slenczka HL, Peters D, Muller G. The aetiology of an unknown human infection transmitted by monkeys (preliminary communication). Ger. Med. Mon.13(1), 1–2 (1968).
   PubMedGoogle Scholar
• Martini GA, Knauff HG, Schmidt HA, Mayer G, Baltzer G. A hitherto unknown infectious disease contracted from monkeys. ‘Marburg-Virus’ Disease. Ger. Med. Mon.13(10), 457–470 (1968).
   PubMedGoogle Scholar
• Martini GA. Marburg agent disease: in man. Trans. R. Soc. Trop. Med. Hyg.63(3), 295–302 (1969).
   PubMedGoogle Scholar
• Martini G. Marburg virus disease. Clinical syndrome. In: Marburg Virus Disease. Martini G, Siegert R (Eds). Springer-Verlag, NY, USA (1971).
   Google Scholar
• Kissling R. Epidemiology of Marburg virus. In: Viruses Affecting Man And Animals. Sanders M (Ed.). Warren H Green Inc., MO, USA, 327–338 (1985).
   Google Scholar
• Stille W, Bohle E. Clinical course and prognosis of Marburg virus (‘Green Monkey’) disease. In: Marburg Virus Disease. Martini GA, Siegert R (Eds). Spring-Verlag, NY, USA 10–18 (1971).
   Google Scholar
• Todorovitch K, Mocitch M, Klasnja R. Clinical picture of two patients infected by the Marburg vervet virus. In: Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA 19–23 (1971).
   Google Scholar
• Stojkovic L, Bordjoski M, Gligic A, Stefanovic Z. Two cases of cercopithecus-monkeys-associated haemorrhagic fever. In: Marburg Virus Disease. GA, Siegert R (Eds). Springer-Verlag, NY, USA 24–33 (1971).
   Google Scholar
• Slenczka WG. The Marburg virus outbreak of 1967 and subsequent episodes. Curr. Top. Microbiol. Immunol.235, 49–75 (1999).
   PubMed Web of Science ®Google Scholar
• Gear JS, Cassel GA, Gear AJ et al. Outbreak of Marburg virus disease in Johannesburg. Br. Med. J.4(5995), 489–493 (1975).
   PubMed Web of Science ®Google Scholar
• Smith DH, Johnson BK, Isaacson M et al. Marburg-virus disease in Kenya. Lancet1(8276), 816–820 (1982).
   PubMed Web of Science ®Google Scholar
• Johnson ED, Johnson BK, Silverstein D et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. Suppl.11, 101–114 (1996).
   PubMedGoogle Scholar
• Nikiforov VV, Turovskii IuI, Kalinin PP et al. A case of a laboratory infection with Marburg fever (Russian). Zh. Mikrobiol. Epidemiol. Immunobiol.(3), 104–106 (1994).
   Google Scholar
• Bausch DG, Nichol ST, Muyemb-Tamfum JJ et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med.355(9), 909–919 (2006).
   PubMedGoogle Scholar
• Bausch DG, Borchert M, Grein T et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of The Congo. Emerg. Infect. Dis.9(12), 1531–1537 (2003).
   PubMedGoogle Scholar
• Feldmann H, Kiley MP. Classification, structure, and replication of filoviruses. Curr. Top. Microbiol. Immunol.235, 1–21 (1999).
   PubMed Web of Science ®Google Scholar
• Sanchez A, Trappier SG, Stroher U, Nichol ST, Bowen MD, Feldmann H. Variation in the glycoprotein and Vp35 genes of Marburg virus strains. Virology240(1), 138–146 (1998).
   PubMedGoogle Scholar
• Towner JS, Khristova ML, Sealy TK et al. Marburg virus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol.80(13), 6497–6516 (2006).
   PubMed Web of Science ®Google Scholar
• Muhlberger E, Lotfering B, Klenk HD, Becker S. Three of the four nucleocapsid proteins of Marburg virus, Np, vp35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J. Virol.72(11), 8756–8764 (1998).
   PubMed Web of Science ®Google Scholar
• Fowler T, Bamberg S, Moller P et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J. Gen. Virol.86(4), 1181–1188 (2005).
   PubMed Web of Science ®Google Scholar
• Jasenosky LD, Kawaoka Y. Filovirus budding. Virus Res.106(2), 181–188 (2004).
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Kuehl K et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS. Immunol. Med. Microbiol.40(1), 27–31 (2004).
   PubMed Web of Science ®Google Scholar
• Bamberg S, Kolesnikova L, Moller P, Klenk HD, Becker S. Vp24 of Marburg virus influences formation of infectious particles. J. Virol.79(21), 13421–13433 (2005).
   PubMedGoogle Scholar
• Basler CF, Wang X, Muhlberger E et al. The Ebola virus Vp35 protein functions as a type I IFN antagonist. Proc. Natl Acad. Sci. USA97(22), 12289–12294 (2000).
   PubMed Web of Science ®Google Scholar
• Reid SP, Leung LW, Hartman AL et al.. Ebola virus Vp24 binds karyopherin α 1 and blocks STAT1 nuclear accumulation. J. Virol.80(11), 5156–5167 (2006).
   PubMed Web of Science ®Google Scholar
• Grosch M, Kash JC, Muhlberger E. Interference of Marburg and Ebola viruses with the type I Ifn response: induction and signaling. Abstract No. 160. XIIIth International Conference On Negative Strand Viruses. Salamanca, Spain (2006).
   Google Scholar
• Feldmann H, Will C, Schikore M, Slenczka W, Klenk HD. Glycosylation and oligomerization of the spike protein of Marburg virus. Virology182(1), 353–356 (1991).
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Volchkova VA, Stroher U et al .Proteolytic processing of Marburg virus glycoprotein. Virology268(1), 1–6 (2000).
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Radoshitzky SR, Guth AC et al. Conserved receptor-binding domains of Lake Victoria Marburgvirus and Zaire Ebola virus bind a common receptor. J. Biol. Chem.281(23), 15951–15958 (2006).
   PubMed Web of Science ®Google Scholar
• Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol.74(10), 4933–4937 (2000).
   PubMed Web of Science ®Google Scholar
• Chan SY, Empig CJ, Welte FJ et al. Folate receptor-α is a cofactor for cellular entry by Marburg and Ebola viruses. Cell106(1), 117–126 (2001).
   PubMed Web of Science ®Google Scholar
• Simmons G, Reeves JD, Grogan CC et al. DC-SIGN and DC-SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology305(1), 115–123 (2003).
   PubMed Web of Science ®Google Scholar
• Marzi A, Gramberg T, Simmons G et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol.78(21), 12090–12095 (2004).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature408(6812), 605–609 (2000).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature424(6949), 681–684 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified Gps. PLOS. Med.3(6), E177 (2006).
   PubMed Web of Science ®Google Scholar
• Gedigk P, Bechtelsheimer H, Korb G. The morbid anatomy of Marburg virus disease. Ger. Med. Mon.14(2), 68–77 Passim (1969).
   PubMedGoogle Scholar
• Geisbert TW, Jaax NK. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct. Pathol.22(1), 3–17 (1998).
   PubMed Web of Science ®Google Scholar
• Murphy F, Van Der Groen G, Whitfield S, Lange J. Ebola and Marburg virus morphology and taxonomy. In: Ebola Haemorrhagic Fever. Pattyn S (Ed.). North-Holland Biomedical Press, The Netherlands 61–82 (1978).
   Google Scholar
• Schnittler HJ, Mahner F, Drenckhahn D, Klenk HD, Feldmann H. Replication of marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease. J. Clin. Invest.91(4), 1301–1309 (1993).
   PubMed Web of Science ®Google Scholar
• Bosio CM, Moore BD, Warfield KL et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology326(2), 280–287 (2004).
   PubMed Web of Science ®Google Scholar
• Bosio CM, Aman MJ, Grogan C et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis.188(11), 1630–1638 (2003).
   PubMed Web of Science ®Google Scholar
• Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol.235, 97–116 (1999).
   PubMed Web of Science ®Google Scholar
• Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/ macrophages. J. Virol.70(4), 2208–2214 (1996).
   PubMed Web of Science ®Google Scholar
• Stroher U, West E, Bugany H, Klenk HD, Schnittler HJ, Feldmann H. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol.75(22), 11025–11033 (2001).
   PubMed Web of Science ®Google Scholar
• Schnittler HJ, Feldmann H. Molecular pathogenesis of Filovirus infections: role of macrophages and endothelial cells. Curr. Top. Microbiol. Immunol.235, 175–204 (1999).
   PubMed Web of Science ®Google Scholar
• Schnittler HJ, Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin. Infect. Dis.27(2), 404–406 (1998).
   PubMed Web of Science ®Google Scholar
• Egbring R, Slenczka W, Baltzer G. Clinical manifestations and mechanism of the haemorrhagic diathesis in Marburg virus disease. In: Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA 42–49 (1971).
   Google Scholar
• Becker S, Spiess M, Klenk HD. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J. Gen. Virol.76(Pt 2), 393–399 (1995).
   PubMed Web of Science ®Google Scholar
• Ignat’ev GM, Strel’tsova MA, Kashentseva EA, Patrushev NA. Effects of tumor necrosis factor antiserum on the course of Marburg hemorrhagic fever. Vestn. Ross. Akad. Med. Nauk.(3), 35–38 (1998).
   Google Scholar
• Ignat’ev GM, Strel’tsova MA, Kashentseva EA. Induction of immunemediators in human cultured mononuclear cells by Marburg virus. Vopr. Virusol.43(4), 169–173 (1998).
   PubMedGoogle Scholar
• Ignat’ev GM, Agafonov AP, Strel’tsova MA et al. A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus. Vopr. Virusol.36(5), 421–423 (1991).
   PubMedGoogle Scholar
• Villinger F, Rollin PE, Brar SS et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, Interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J. Infect. Dis.179(Suppl. 1), S188–S191 (1999).
   PubMed Web of Science ®Google Scholar
• Almeida JD, Waterson AP, Simpson DIH. Morphology and morphogenesis of the Marburg agent. In: Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA 84–97 (1971).
   Google Scholar
• Bwaka MA, Bonnet MJ, Calain P et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of The Congo: clinical observations in 103 patients. J. Infect. Dis.179(Suppl. 1), S1–S7 (1999).
   Web of Science ®Google Scholar
• Anonymous. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/ International Study Team. Bull. World Health Organ.56(2), 247–270 (1978).
   Google Scholar
• Pattyn S, van der Groen G, Courteille G, Jacob W, Piot P. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet1(8011), 573–574 (1977).
   PubMed Web of Science ®Google Scholar
• Ryabchikova E, Strelets L, Kolesnikova L, Pyankov O, Sergeev A. respiratory Marburg virus infection in guinea pigs. Arch. Virol.141(11), 2177–2190 (1996).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Geisbert JB et al. Development of postexposure treatments for Ebola and Marburg hemorrhagic fevers. In: Filoviruses: Recent Advances and Future Challenges. Winnipeg, Canada (2006).
   Google Scholar
• Simpson DI, Zlotnik I, Rutter DA. Vervet monkey disease. Experiment infection of guinea pigs and monkeys with the causative agent. Br. J. Exp. Pathol.49(5), 458–464 (1968).
   PubMed Web of Science ®Google Scholar
• Agafonov AP, Ignat’ev GM, Kuz’min VA, Akimenko ZL, Kosareva TV, Kashentseva EA. Immunogenic properties of Marburg virus proteins. Vopr. Virusol.1, 58–61 (1992).
   Google Scholar
• Ignat’ev GM, Strel’tsova MA, Agafonov AP, Zhukova NA, Kashentseva EA, Vorob’eva MS. The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus. Vopr. Virusol.39(1), 13–17 (1994).
   PubMedGoogle Scholar
• Donchenko VV, Lebedev VN, Markin VA, Firsova IV. Effectiveness of virus-specific proteins in immunogenesis during experimental Marburg fever. Vopr. Virusol.41(5), 216–218 (1996).
   PubMedGoogle Scholar
• Hevey M, Negley D, Geisbert J, Jahrling PB, Schmaljohn A. Recombinant Marburg virus glycoprotein subunit vaccine protects guinea pigs from lethal infection. In: Vaccines 97: Molecular Approaches to the Control of Infectious Diseases. Brown F, Burton DR, Doherty P, Mekalanos J, Norrby E (Eds). Cold Spring Harbor Laboratory Press, NY, USA 93–98 (1997).
   Google Scholar
• Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology251(1), 28–37 (1998).
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Vanderzanden L et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine20(3–4), 586–593 (2001).
   PubMed Web of Science ®Google Scholar
• Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine21(25–26), 4071–4080 (2003).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine22(25–26), 3495–3502 (2004).
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine23(23), 3033–3042 (2005).
   PubMed Web of Science ®Google Scholar
• Wang D, Hevey M, Juompan LY et al. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology353(2), 324–332 (2006).
   PubMed Web of Science ®Google Scholar
• Simpson DIH, Bowen ETW, Bright WF. Vervet monkey disease: experimental infection of monkeys with the causative agent, and antibody studies in wild-caught monkeys. Lab. Anim.2, 75–81 (1968).
   Google Scholar
• Simpson DI. Marburg agent disease: in monkeys. Trans. R. Soc. Trop. Med. Hyg.63(3), 303–309 (1969).
   PubMed Web of Science ®Google Scholar
• Haas R, Maass G. Experimental infection of monkeys with the Marburg virus. In: Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA 136–143 (1971).
   Google Scholar
• Oehlert W. The morphological picture in livers, spleens, and lymph nodes of monkeys and guinea pigs after infection with the ‘vervet agent’. In: Marburg Virus Disease. Martini G, Siegert R (Eds). Springer-Verlag, NY, USA 144–156 (1971).
   Google Scholar
• Murphy FA, Simpson DI, Whitfield SG, Zlotnik I, Carter GB. Marburg virus infection in monkeys. ultrastructural studies. Lab. Invest.24(4), 279–291 (1971).
   PubMedGoogle Scholar
• Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med.11(7), 786–790 (2005).
   PubMed Web of Science ®Google Scholar
• Daddario-Dicaprio KM, Geisbert TW, Stroher U et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet367(9520), 1399–1404 (2006).
   PubMed Web of Science ®Google Scholar
• Daddario-Dicaprio KM, Geisbert TW, Geisbert JB et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol.80(19), 9659–9666 (2006).
   PubMed Web of Science ®Google Scholar
• Gonchar NI, Pshenichnov VA, Pokhodiaev VA, Lopatov KL, Firsova IV. The sensitivity of different experimental animals to the Marburg virus. Vopr. Virusol.36(5), 435–437 (1991).
   PubMed Web of Science ®Google Scholar
• Spiridonov VA, Bazhutin NB, Belanov EF et al. Changes in the blood serum aminotransferase activity in the experimental infection of Cercopithecus aethiops monkeys with the Marburg virus. Vopr. Virusol.37(3), 156–157 (1992).
   PubMedGoogle Scholar
• Zlotnik I. Marburg agent disease: pathology. Trans. R. Soc. Trop. Med. Hyg.63(3), 310–327 (1969).
   PubMedGoogle Scholar
• Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest.80(2), 171–186 (2000).
   PubMed Web of Science ®Google Scholar
• Peters CJ, Sanchez A, Feldmann H, Rollin PE, Nichol S, Ksiazek TG. Filoviruses as emerging pathogens. Semin. Virol.5(2), 147–154 (1994).
   Google Scholar
• Chepurnov AA, Tuzova MN, Ternovoy VA, Chernukhin IV. Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa gp viral protein. Immunol. Lett.68(2–3), 257–261 (1999).
   PubMed Web of Science ®Google Scholar
• Nabel GJ. Surviving Ebola virus infection. Nat. Med.5(4), 373–374 (1999).
   PubMedGoogle Scholar
• Jahrling PB, Geisbert TW, Geisbert JB et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J. Infect. Dis.179(Suppl. 1), S224–S234 (1999).
   Google Scholar
• Jahrling PB, Geisbert J, Swearengen JR et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl.11, 135–140 (1996).
   PubMedGoogle Scholar
• Ksiazek TG, West CP, Rollin PE, Jahrling PB, Peters CJ. Elisa for the detection of antibodies to Ebola viruses. J. Infect. Dis.179(Suppl. 1), S192–S198 (1999).
   Web of Science ®Google Scholar
• Ksiazek TG, Rollin PE, Williams AJ et al. Clinical virology of Ebola hemorrhagic fever (Ehf): virus, virus antigen, and IgG and IgM antibody findings among Ehf patients in Kikwit, Democratic Republic of The Congo, 1995. J. Infect. Dis.179(Suppl. 1), S177–S187 (1999).
   PubMed Web of Science ®Google Scholar
• Sanchez A, Ksiazek TG, Rollin PE et al. Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J. Infect. Dis.179(Suppl. 1), S164–S169 (1999).
   PubMed Web of Science ®Google Scholar
• Zaki SR, Shieh WJ, Greer PW et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte Contre les Epidemies a Kikwit. J. Infect. Dis.179(Suppl. 1), S36–S47 (1999).
   PubMed Web of Science ®Google Scholar
• Grolla A, Lucht A, Dick D, Strong JE, Feldmann H. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull. Soc. Pathol. Exot.98(3), 205–209 (2005).
   PubMedGoogle Scholar
• Mupapa K, Massamba M, Kibadi K et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis.179(Suppl. 1), S18–S23 (1999).
   PubMed Web of Science ®Google Scholar
• Borisevich IV, Mikhailov VV, Krasnianskii VP et al. [Development and study of the properties of immunoglobulin against Ebola fever]. Vopr. Virusol.40(6), 270–273 (1995).
   PubMedGoogle Scholar
• Geisbert TW, Hensley LE, Jahrling PB et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet362(9400), 1953–1958 (2003).
   PubMed Web of Science ®Google Scholar
• Boumandouki P, Formenty P, Epelboin A et al. Clinical management of patients and deceased during the Ebola outbreak from October to December 2003 in Republic of Congo. Bull. Soc. Pathol. Exot.98(3), 218–223 (2005).
   PubMedGoogle Scholar
• Hewlett BS, Amola RP. Cultural contexts of Ebola in northern Uganda. Emerg. Infect. Dis.9(10), 1242–1248 (2003).
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology239(1), 206–216 (1997).
   PubMed Web of Science ®Google Scholar
• Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA. Inactivated Marburg virus elicits a nonprotective immune response in rhesus monkeys. J. Biotechnol.44(1–3), 111–118 (1996).
   PubMed Web of Science ®Google Scholar
• Agafonova OA, Viazunov SA, Zhukov VA et al. Relationship between the level of specific antibodies with disease outcome in cercopithecus aethiops monkeys in experimental Marburg disease. Vopr. Virusol.42(3), 109–111 (1997).
   PubMedGoogle Scholar
• Ignat’ev GM, Strel’tsova MA, Agafonov AP, Kashentseva EA. Mechanisms of protective immune response in models of Marburg fever in monkeys. Vopr. Virusol.40(3), 109–113 (1995).
   PubMedGoogle Scholar
• Becker S, Volchkov VE, Muhleberger E, Al E. A recombinant vaccinia virus expressing the surface glycoprotein of Marburg virus does not protect guinea pigs against Marburg virus-infection. In: Xth International Congress of Virology. Jerusalem, Israel (1996)
   Google Scholar
• Sanger C, Muhlberger E, Klenk HD, Becker S. Adverse effects of Mva-T7 on the transport of Marburg virus glycoprotein. J. Virol. Methods91(1), 29–35 (2001).
   PubMedGoogle Scholar
• Amorosa VK, Isaacs SN. Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome. Clin. Infect. Dis.37(3), 426–432 (2003).
   PubMedGoogle Scholar
• Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin. Biol. Ther.1(2), 177–191 (2001).
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines2(3), 447–459 (2003).
   PubMedGoogle Scholar
• Hevey M, Negley D, Staley A, Schmaljohn A. Determination of vaccine components required for protecting cynomolgus macaques against genotypically divergent isolates of Marburg virus. Abstract No. W36–4. In: 20th Annual Meeting of The American Society For Virology. WI, USA (2001)
   Google Scholar
• Sullivan N. Elements of vaccine-induced protective immunity against filovirus infection. In: Filoviruses: Recent Advances And Future Challenges. Winnipeg, Canada (2006).
   Google Scholar
• Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus Vp40 drives the formation of virus-like filamentous particles along with Gp. J. Virol.76(10), 4855–4865 (2002).
   PubMed Web of Science ®Google Scholar
• Licata JM, Johnson RF, Han Z, Harty RN. Contribution of Ebola virus glycoprotein, nucleoprotein, and Vp24 to budding of Vp40 virus-like particles. J. Virol.78(14), 7344–7351 (2004).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, Aman MJ, Bavari S. Virus-like particle-based vaccines protect nonhuman primates against lethal Ebola virus infection. In: Filoviruses: Recent Advances And Future Challenges. Winnipeg, Canada (2006)
   Google Scholar
• Pattenden LK, Middelberg AP, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol.23(10), 523–529 (2005).
   PubMed Web of Science ®Google Scholar
• Lehrman S. Virus treatment questioned after gene therapy death. Nature401(6753), 517–518 (1999).
   PubMed Web of Science ®Google Scholar
• Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol. Ther.10(4), 616–629 (2004).
   PubMed Web of Science ®Google Scholar
• Boyer JL, Kobinger G, Wilson JM, Crystal RG. Adenovirus-based genetic vaccines for biodefense. Hum. Gene. Ther.16(2), 157–168 (2005).
   PubMed Web of Science ®Google Scholar
• Hitt MM, Gauldie J. Gene vectors for cytokine expression in vivo. Curr. Pharm. Des.6(6), 613–632 (2000).
   PubMed Web of Science ®Google Scholar
• Kobinger G. Circumventing the presence of pre-existing immunity to adenovirus vaccine vector with new serotypes or immunization strategies. In: Filoviruses: Recent Advances and Future Challenges. Winnipeg, Canada (2006).
   Google Scholar
• Schulick AH, Vassalli G, Dunn PF et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J. Clin. Invest.99(2), 209–219 (1997).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Poveda GA, Ramsey B, Mccoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics101(6), 1013–1019 (1998).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Pau MG, Custers JH et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol.172(10), 6290–6297 (2004).
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Feldmann H, Zhi Y et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology346(2), 394–401 (2006).
   PubMed Web of Science ®Google Scholar
• Murakami P, Pungor E, Files J et al. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum. Gene. Ther.13(8), 909–920 (2002).
   PubMedGoogle Scholar
• Fallaux FJ, Bout A, van der Velde I et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene. Ther.9(13), 1909–1917 (1998).
   PubMed Web of Science ®Google Scholar
• Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol.73(5), 3723–3732 (1999).
   PubMed Web of Science ®Google Scholar
• Rose NF, Roberts A, Buonocore L, Rose JK. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol.74(23), 10903–10910 (2000).
   PubMed Web of Science ®Google Scholar
• Rose NF, Marx PA, Luckay A et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell106(5), 539–549 (2001).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Althage A, Holland J. Target antigens for H-2-restricted vesicular stomatitis virus-specific cytotoxic T cells. J. Immunol.121(2), 744–748 (1978).
   PubMedGoogle Scholar
• Zinkernagel RM, Adler B, Holland JJ. Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp. Cell. Biol.46(1–2), 53–70 (1978).
   PubMedGoogle Scholar
• Fehr T, Bachmann MF, Bluethmann H, Kikutani H, Hengartner H, Zinkernagel RM. T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signal. Cell Immunol.168(2), 184–192 (1996).
   PubMed Web of Science ®Google Scholar
• Reif JS, Webb PA, Monath TP et al. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am. J. Trop. Med. Hyg.36(1), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Gaidamovich S, Uvarov VN, Alekseeva AA. Isolation of vesicular stomatitis virus from a patient. Vopr. Virusol.11(1), 77–80 (1966).
   PubMedGoogle Scholar
• Quiroz E, Moreno N, Peralta PH, Tesh RB. A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am. J. Trop. Med. Hyg.39(3), 312–314 (1988).
   PubMed Web of Science ®Google Scholar
• Johnson JE, Nasar F, Coleman JW et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology (2006).
   PubMedGoogle Scholar
• Martinez I, Rodriguez LL, Jimenez C, Pauszek SJ, Wertz GW. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J. Virol.77(14), 8039–8047 (2003).
   PubMed Web of Science ®Google Scholar
• Daddario-Dicaprio KM, Geisbert TW, Stroher U et al. Postexposure protection against Marburg hemorrhagic fever with a recombinant vaccine in nonhuman primates; how does it work? In: Filoviruses: Recent Advances and Future Challenges. Winnipeg, Canada (2006).
   Google Scholar
• Tesh RB, Johnson KM. Vesicular stomatitis. In: Diseases Transmitted From Animals to Man. Hubbert WT, Mccolloch WF, Schnurrenberger PR (Eds). CC Thomas, IL, USA 897–910 (1975).
   Google Scholar
• Hanson RP. The natural history of vesicular stomatitis. Bacteriol. Rev.16(3), 179–204 (1952).
   PubMedGoogle Scholar
• Slate D, Rupprecht CE, Rooney JA, Donovan D, Lein DH, Chipman RB. Status of oral rabies vaccination in wild carnivores in the United States. Virus Res.111(1), 68–76 (2005).
   PubMedGoogle Scholar
• Publicover J, Ramsburg E, Rose JK. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J. Virol.79(21), 13231–13238 (2005).
   PubMed Web of Science ®Google Scholar
• Roberts DM, Nanda A, Havenga MJ et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature441(7090), 239–243 (2006).
   PubMed Web of Science ®Google Scholar
• Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol.77(1), 799–803 (2003).
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol. (2006).
   Google Scholar
• Enterlein S, Volchkov V, Weik M et al. Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein Vp30. J. Virol.80(2), 1038–1043 (2006).
   PubMedGoogle Scholar
• Feldmann H. Reverse genetics systems for high-containment viruses: development and potential use. In: Rational Design of Vaccines and Immunotherapeutics. Bioterrorism and Emerging Infectious Diseases: Antimicrobials, Therapeutics and Immune-Modulators (Joint Conference). Keystone Symposia, Keystone, CO, USA 92 (2004).
   Google Scholar
• Feldmann H, Slenczka W, Klenk HD. Emerging and reemerging of filoviruses. Arch. Virol. Suppl.11, 77–100 (1996).
   PubMedGoogle Scholar
• Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, Peters CJ. Filoviridae: Marburg and Ebola viruses. In: Fields’ Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PN, USA 1279–1304 (2001).
   Google Scholar